pursuant to regulation 30 of SEBI LODR, 2015: Allotment of Equity shares in the Board meeting dated 13.03.2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India Ltd has converted 55 lakh warrants into an equal number of equity shares at Rs. 49 per share (face value Rs. 10 + premium of Rs. 39), issued on a preferential basis to members of the Promoter and Promoter Group. The company received Rs. 20.21 crores as the balance 75% consideration (Rs. 36.75 per warrant) from the allottees. Following this allotment, the company's paid-up equity capital has increased to Rs. 49.01 crores, comprising 4.90 crore equity shares of Rs. 10 each. The promoter group's shareholding has risen from 55.92% to 60.86%, while public shareholding has diluted from 44.08% to 39.14%. The warrants were originally allotted on February 4, 2025, and have been converted within the 18-month window permitted under SEBI ICDR Regulations.
The conversion strengthens promoter commitment by infusing Rs. 20.21 crores of fresh capital while increasing promoter stake by nearly 5 percentage points, which is mildly positive for governance confidence but dilutes existing public shareholders. The stock may see a short-term overhang as supply increases, though the capital raise improves the company's equity base.